155 results on '"Thorstad W"'
Search Results
2. Lack of Association of Cadherin Expression and Histopathologic Type, Metastasis, or Patient Outcome in Oropharyngeal Squamous Cell Carcinoma: A Tissue Microarray Study
3. EP-1202 Associations between smoking cessation after radiotherapy for larynx cancer and patient outcomes
4. Multicenter phase II trial of nab-paclitaxel and cisplatin (AP) followed by chemoradiation therapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC)
5. Prognostic Groups for p16-Positive Oropharyngeal Squamous Cell Cancer (p16-OPSCC) Treated With Chemoradiation Therapy (CRT) in NRG Oncology/RTOG 0129 and 0522
6. Validation of NRG Oncology/RTOG 0129 Risk Groups for p16-Positive and p16-Negative Oropharyngeal Squamous Cell Cancer (OPSCC)
7. 1067P - Multicenter phase II trial of nab-paclitaxel and cisplatin (AP) followed by chemoradiation therapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC)
8. A framework for automated contour quality assurance in radiation therapy including adaptive techniques
9. SU-C-210-07: Assessment of Intra-/Inter-Fractional Internal Tumor and Organ Movement in Radiotherapy of Head and Neck Cancer Using On-Board Cine MRI
10. WE-G-BRD-04: BEST IN PHYSICS (JOINT IMAGING-THERAPY): An Integrated Model-Based Intrafractional Organ Motion Tracking Approach with Dynamic MRI in Head and Neck Radiotherapy
11. PO-0885: Validation of a head and neck DVH prediction model for use in commercially available knowledge-based planning software
12. WE‐E‐BRE‐09: Investigation of the Association Between Radiation‐Induced Pain and Radiation Dose in Head and Neck Cancer Patients
13. TU-C-17A-03: An Integrated Contour Evaluation Software Tool Using Supervised Pattern Recognition for Radiotheray
14. TU-C-17A-04: BEST IN PHYSICS (THERAPY) - A Supervised Framework for Automatic Contour Assessment for Radiotherapy Planning of Head- Neck Cancer
15. SU-E-T-312: Test of the Generalized Tumor Dose (gTD) Model with An Independent Lung Tumor Dataset
16. Clinical implementation of dose-volume histogram predictions for organs-at-risk in IMRT planning
17. Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-HNSCC): Can HPV Help Decide Which Agent?
18. Nasopharynx Carcinoma at a University: Outcomes With Transitioning to IMRT and Chemotherapy
19. Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck (LA-HNSCC): Can HPV Help Decide Which Agent?
20. Outcomes of Diabetic Metformin Versus Nonmetformin Users With Oropharynx Carcinoma Treated With IMRT
21. A New Tumor Control Probability Model Fitted to Head-and-Neck and Lung Local Control Data and Resulting Implications for the Impact of Dose Heterogeneity
22. SU-E-T-244: Interfractional Motion Simulation of Head and Neck and Lung Patients Correlated to Treatment Outcome
23. MVCT-Detector Data Sinograms for In Vivo Quality Assurance of Helical Tomotherapy Treatments of Head-and-Neck Cancer Patients
24. Outcomes of Concurrent Chemoradiation Therapy (CRT) Versus Induction Plus CRT (ICRT) for Oropharynx Carcinoma
25. SU-E-J-176: Clinical Evaluations of a Novel Metal Artifact Reduction Technique for Treatment Planning in Radiation Therapy
26. TH-C-213AB-08: The Cell-Kill-Based Equivalent Uniform Dose (cEUD) Predictor: A Modification to Account for Increasing Radioresistance with Increasing Tumor Volume
27. Lack of Association of Cadherin Expression and Histopathologic Type, Metastasis, or Patient Outcome in Oropharyngeal Squamous Cell Carcinoma: A Tissue Microarray Study
28. Impact of Anatomic Changes on Sinus Carcinoma Proton Radiotherapy Utilizing Serial Multi-Modality Imaging
29. The Potential of using a Commercial Treatment Planning System for Physician Quality Reporting for Maintenance of ABR Certification and CMS Reimbursement
30. IMRT for Oropharyngeal Carcinoma: Impact of Nodal Volume and HPV Status
31. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting
32. SU-E-T-01: Tumor Control Probability Models Derived Using Machine Learning for Head and Neck and Lung Tumors including a New Metric, Total Clonogen Survival (TCS)
33. SU-E-T-295: Clinical Evaluations of a Novel Metal Artifact Reduction Technique for Helical CT Scans in Radiation Therapy
34. SU‐E‐J‐72: In Vivo Quality Assurance of Head and Neck Cancer IMRT Treatments Using TomoTherapyˈˈs Exit Detector Data
35. SU-E-I-16: CBCT with Flexible Imaging Trajectories to Improve Image Quality and Longitudinal Coverage - Concept, Simulation and Digital Phantom Study
36. Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
37. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).
38. Safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in 30 patients (pts) with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).
39. 134 oral XEROSTOMIA PATIENT REPORTED OUTCOMES ARE A LINEAR FUNCTION OF CONTRALATERAL PAROTID GLAND MEAN DOSE
40. TomoTherapy's Exit Detector Data for In vivo Quality Assurance of Head and Neck Treatments
41. Clinical response rate at primary tumor site by WHO criteria following an induction chemotherapy regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).
42. Outcomes in HPV-associated oropharyngeal squamous cell carcinoma after postoperative or definitive nonsurgical therapy.
43. Interim safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-)paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).
44. TH-D-213A-04: Application of Supervised Spectral Clustering for PET Tumor Delineation: A Phantom Study
45. TH-D-213A-02: An Improved Iterative Thresholding Approach for 3D PET Tumor Delineation: Phantom Study
46. SU‐FF‐J‐51: The Impact of Source‐To‐Background Ratio, Tumor Size, Scan Duration, and Smoothing Filter On a Two‐Stage PET Tumor Segmentation Method
47. Survival for nasopharyngeal cancer with distant metastatic disease at presentation
48. SU‐GG‐I‐105: A Process to Determine Optimal Oblique Contouring Planes
49. SU-GG-J-03: 3D Pathology Validation for Head-And-Neck Tumor Segmentation in PET/CT/MRI Images
50. SU-GG-J-192: Use of Optimized Oblique Anatomical Planes for Efficient and Accurate Organ and Tumor Segmentation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.